Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04089579 · ClinicalTrials.gov registry record · Phase 2
hCT-MSC in Children With Autism Spectrum Disorder
A Phase 2 study of Autism Spectrum Disorder and Autism, sponsored by Joanne Kurtzberg, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
- 1
- Study location
NCT04089579 is a Phase 2 study of Autism Spectrum Disorder and Autism that has completed, run by Joanne Kurtzberg, MD. The registered enrollment target is 137 participants, roughly in line with the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT04089579, a Phase 2 study of Autism Spectrum Disorder and Autism, has completed, sponsored by Joanne Kurtzberg, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Phase II study is to determine the efficacy of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) for improving social communication abilities in children with autism spectrum disorder (ASD).
Conditions Studied
Interventions
- OTHER Placebo Infusion
- BIOLOGICAL Cord Tissue Mesenchymal Stromal Cells
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2020-10-12 |
| Est. Completion | 2024-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04089579
The ClinicalTrials.gov registry entry for NCT04089579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target. The listed sponsor is Joanne Kurtzberg, MD, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo Infusion is the first listed.
NCT04089579 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04089579 about?
NCT04089579 is a clinical study titled "hCT-MSC in Children With Autism Spectrum Disorder". The purpose of this Phase II study is to determine the efficacy of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) for improving social communication abilities in children with autism spectrum disorder (ASD).
What is the current status of trial NCT04089579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2020-10-12. Estimated completion is 2024-02-01.
What conditions does trial NCT04089579 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Autism.
What interventions are being tested in trial NCT04089579?
The interventions under investigation include: Placebo Infusion (OTHER), Cord Tissue Mesenchymal Stromal Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04089579?
This trial is sponsored by Joanne Kurtzberg, MD, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04089579 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.